Sign In
Buy REGN
$628.73
+9.78 (+1.58%)
At Close: Jun 04, 2026
Law Offices of Frank R. Cruz Encourages Regeneron Pharmaceuticals, Inc. (REGN) Investors To Inquire About Securities Fraud Class Action
02:53pm, Wednesday, 08'th Jan 2025
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz Encourages Regeneron Pharmaceuticals, Inc. (REGN) Investors To Inquire About Securities Fraud Class Action.
REGENERON THERAPEUTICS, INC. (NASDAQ: REGN) INVESTOR ALERT: Investors With Large Losses in Regeneron Therapeutics, Inc. Should Contact Bernstein Liebhard
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces that it has filed a class action lawsuit in the United States District Court for the Southern District of New York, capt
TARRYTOWN, N.Y., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2024 financial and operating resu
Regeneron's Diversified Growth Makes It My Top Biopharma Pick For 2025
10:00am, Sunday, 05'th Jan 2025
Regeneron Pharmaceuticals continues to show strong growth, driven by Dupixent's FDA approval for COPD and Eylea HD's market resilience against biosimilars. Q3 earnings beat expectations with $3.72 bil
1 Beaten-Down Stock That Could Soar by 50% in 2025, According to Wall Street
10:00am, Thursday, 02'nd Jan 2025
Biotech giant Regeneron Pharmaceuticals (REGN 1.08%) started 2024 on a strong note and performed well through the first half of the year. However, the drugmaker has since seen its shares decline subst
Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results
07:00am, Thursday, 19'th Dec 2024
Investigational REGN7508 (catalytic domain) and REGN9933 (A2 domain) are being evaluated for their potential to control thrombosis while minimizing bleeding risk in a variety of patient populations an
REGN's Eylea HD Shows Non-Inferiority to Eylea in Eye Disease Study
11:21am, Wednesday, 18'th Dec 2024
Regeneron's phase III study evaluating Eylea HD against stand-of-care Eylea treatment meets the primary endpoint of non-inferior visual gain in RVO patients.
Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
04:05pm, Tuesday, 17'th Dec 2024
TARRYTOWN, N.Y., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January
Regeneron Named to Dow Jones Sustainability World Index for Sixth Consecutive Year
04:30pm, Monday, 16'th Dec 2024
TARRYTOWN, N.Y., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced its sixth consecutive inclusion in the Dow Jones Sustainability World Index (DJSI Worl
Regeneron Down 15.5% Year to Date: How to Play the Stock?
10:10am, Friday, 13'th Dec 2024
REGN's lead drug, Eylea, faces a rapid decline in sales, which has impacted overall performance, even though Dupixent maintains momentum. We advise investors to wait and watch for now.
Biotech Roundup: 3 Stocks to Watch
03:35pm, Wednesday, 11'th Dec 2024
Most recently in the ever-growing biotech industry , investors are musing over potential changes to the sector after President-elect Donald Trump picked Martin “Marty” Makary to be the U.S. Food a
Lost Money on Regeneron Pharmaceuticals, Inc.(REGN)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky
07:25am, Tuesday, 10'th Dec 2024
NEW YORK, NY / ACCESSWIRE / December 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Regeneron Pharmaceuticals, Inc. ("Regeneron Pharmaceuticals, Inc.") (NASDA
Odronextamab ASH Presentations Underscore Impressive Potential in Earlier Lines of Treatment and Additional Types of Lymphoma
05:45pm, Monday, 09'th Dec 2024
Odronextamab monotherapy led to complete responses in all patients with previously untreated follicular lymphoma evaluable for efficacy, per initial results from the safety lead-in portion of the conf
NEW YORK, NY / ACCESSWIRE / December 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Regeneron Pharmaceuticals, Inc. ("Regeneron Pharmaceuticals, Inc.") (NASDAQ
